Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 3.34
ACRX's Cash-to-Debt is ranked higher than
56% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. ACRX: 3.34 )
Ranked among companies with meaningful Cash-to-Debt only.
ACRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31  Med: 3.73 Max: N/A
Current: 3.34
Equity-to-Asset -0.22
ACRX's Equity-to-Asset is ranked lower than
93% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ACRX: -0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
ACRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.22  Med: 0.42 Max: 0.69
Current: -0.22
-0.22
0.69
Piotroski F-Score: 1
Altman Z-Score: -3.72
Beneish M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -203.59
ACRX's Operating Margin % is ranked lower than
83% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. ACRX: -203.59 )
Ranked among companies with meaningful Operating Margin % only.
ACRX' s Operating Margin % Range Over the Past 10 Years
Min: -1805.22  Med: -452.89 Max: -22.6
Current: -203.59
-1805.22
-22.6
Net Margin % -273.65
ACRX's Net Margin % is ranked lower than
84% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. ACRX: -273.65 )
Ranked among companies with meaningful Net Margin % only.
ACRX' s Net Margin % Range Over the Past 10 Years
Min: -1875.09  Med: -443.98 Max: -79.4
Current: -273.65
-1875.09
-79.4
ROE % -1567.90
ACRX's ROE % is ranked lower than
98% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ACRX: -1567.90 )
Ranked among companies with meaningful ROE % only.
ACRX' s ROE % Range Over the Past 10 Years
Min: -1567.9  Med: -61.17 Max: -43.78
Current: -1567.9
-1567.9
-43.78
ROA % -45.09
ACRX's ROA % is ranked lower than
74% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. ACRX: -45.09 )
Ranked among companies with meaningful ROA % only.
ACRX' s ROA % Range Over the Past 10 Years
Min: -134.55  Med: -63.33 Max: -22.78
Current: -45.09
-134.55
-22.78
ROC (Joel Greenblatt) % -371.88
ACRX's ROC (Joel Greenblatt) % is ranked lower than
77% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. ACRX: -371.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1434.7  Med: -878.27 Max: -173.98
Current: -371.88
-1434.7
-173.98
3-Year Revenue Growth Rate -19.80
ACRX's 3-Year Revenue Growth Rate is ranked lower than
83% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ACRX: -19.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.9 Max: 58.9
Current: -19.8
0
58.9
3-Year EBITDA Growth Rate 61.10
ACRX's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. ACRX: 61.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.2 Max: 61.1
Current: 61.1
0
61.1
3-Year EPS without NRI Growth Rate 17.20
ACRX's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ACRX: 17.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -45.7 Max: 17.2
Current: 17.2
0
17.2
GuruFocus has detected 5 Warning Signs with AcelRx Pharmaceuticals Inc $ACRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACRX's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ACRX Guru Trades in Q2 2015

Paul Tudor Jones 24,100 sh (-54.18%)
» More
Q3 2015

ACRX Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q2 2016

ACRX Guru Trades in Q2 2016

Jim Simons 21,100 sh (New)
» More
Q3 2016

ACRX Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3829
Compare:NAS:NVCN, NAS:SPNE, OTCPK:PHMZF, NAS:IRIX, OTCPK:DMTRF, NAS:CGNT, NAS:NVTR, NAS:VIVE, NAS:MSON, NAS:IRMD, NAS:FONR, NAS:EDAP, NAS:SPAN, NAS:DRAD, NAS:OBLN, NAS:EYES, OTCPK:TITXF, NAS:SRTS, OTCPK:IVOB, NAS:PAVM » details
Traded in other countries:R5X.Germany,
Headquarter Location:USA
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.

AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. Its product candidate, DSUVIA (known as ARX-04 outside of the United States), and follow-on product candidate, ZALVISO, utilize sublingual sufentanil, delivered via a non-invasive route of administration.

Ratios

vs
industry
vs
history
PS Ratio 6.62
ACRX's PS Ratio is ranked lower than
81% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ACRX: 6.62 )
Ranked among companies with meaningful PS Ratio only.
ACRX' s PS Ratio Range Over the Past 10 Years
Min: 4.69  Med: 27.76 Max: 2370
Current: 6.62
4.69
2370
EV-to-EBIT -1.85
ACRX's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. ACRX: -1.85 )
Ranked among companies with meaningful EV-to-EBIT only.
ACRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -158.7  Med: -3.4 Max: 107.8
Current: -1.85
-158.7
107.8
EV-to-EBITDA -1.97
ACRX's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. ACRX: -1.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -201.3  Med: -3.7 Max: 93.6
Current: -1.97
-201.3
93.6
Current Ratio 6.11
ACRX's Current Ratio is ranked higher than
93% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. ACRX: 6.11 )
Ranked among companies with meaningful Current Ratio only.
ACRX' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.84 Max: 20.39
Current: 6.11
0.43
20.39
Quick Ratio 5.97
ACRX's Quick Ratio is ranked higher than
94% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. ACRX: 5.97 )
Ranked among companies with meaningful Quick Ratio only.
ACRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.77 Max: 20.39
Current: 5.97
0.43
20.39
Days Inventory 43.36
ACRX's Days Inventory is ranked higher than
90% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. ACRX: 43.36 )
Ranked among companies with meaningful Days Inventory only.
ACRX' s Days Inventory Range Over the Past 10 Years
Min: 38.83  Med: 43.44 Max: 48.05
Current: 43.36
38.83
48.05
Days Sales Outstanding 56.67
ACRX's Days Sales Outstanding is ranked lower than
83% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. ACRX: 56.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.67  Med: 92.46 Max: 122.66
Current: 56.67
56.67
122.66
Days Payable 47.95
ACRX's Days Payable is ranked lower than
61% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ACRX: 47.95 )
Ranked among companies with meaningful Days Payable only.
ACRX' s Days Payable Range Over the Past 10 Years
Min: 46.18  Med: 184.04 Max: 321.9
Current: 47.95
46.18
321.9

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.70
ACRX's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ACRX: -1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -303.2  Med: -18.8 Max: 0
Current: -1.7
-303.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.24
ACRX's Price-to-Median-PS-Value is ranked higher than
93% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ACRX: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.15 Max: 76.5
Current: 0.24
0
76.5
Earnings Yield (Greenblatt) % -54.17
ACRX's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ACRX: -54.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -54.94  Med: 3.75 Max: 9.1
Current: -54.17
-54.94
9.1

More Statistics

Revenue (TTM) (Mil) $17.44
EPS (TTM) $ -1.04
Beta2.84
Short Percentage of Float12.46%
52-Week Range $2.25 - 4.08
Shares Outstanding (Mil)45.38

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 13 41 93
EPS ($) -1.11 -0.71 0.06
EPS without NRI ($) -1.11 -0.71 0.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update May 08 2017 
AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on M Apr 26 2017 
AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual P Apr 13 2017 
AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual Regio Apr 06 2017 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceutica Oct 15 2014 
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
ETFs with exposure to AcelRx Pharmaceuticals, Inc. : May 22, 2017 May 22 2017
AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
AcelRx Pharmaceuticals reports 1Q loss May 08 2017
AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update May 08 2017
Investor Network: AcelRx Pharmaceuticals, Inc. to Host Earnings Call May 08 2017
AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on... Apr 26 2017
AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual... Apr 13 2017
ETFs with exposure to AcelRx Pharmaceuticals, Inc. : April 11, 2017 Apr 11 2017
AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual... Apr 06 2017
Edited Transcript of ACRX earnings conference call or presentation 2-Mar-17 9:30pm GMT Apr 04 2017
European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30... Mar 28 2017
ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 27, 2017 Mar 27 2017
AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April Mar 17 2017
AcelRx Pharmaceuticals, Inc. to Present at The MicroCap Conference on April 4th in New York City at... Mar 16 2017
AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA™ at Upcoming Congresses Mar 16 2017
AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)